Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. - Wikidata - wikimedia - TriplyDB

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

http://www.wikidata.org/entity/Q34455153

about

Clinical trials in severe sepsis with drotrecogin alfa (activated)Immunomodulation in sepsis: state of the art and future perspective Recombinant human activated protein C for severe sepsis in neonates Human recombinant activated protein C for severe sepsis Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients Human recombinant activated protein C for severe sepsis Human recombinant activated protein C for severe sepsis Recombinant human activated protein C for severe sepsis in neonates Challenging orthodoxy in critical care trial design: physiological responsiveness Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal Prospects for vaccine prevention of meningococcal infection Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis.Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation.Advances in the management of sepsis and the understanding of key immunologic defects PAMPs and DAMPs as triggers for DIC Drotrecogin alfa (activated)...a sad final fizzle to a roller-coaster party Sepsis and ARDS: The Dark Side of Histones Pharmacological inhibitors of TRPV4 channels reduce cytokine production, restore endothelial function and increase survival in septic mice Strategies to Reduce Mortality from Bacterial Sepsis in Adults in Developing Countries Coagulation abnormalities in critically ill patients Performance of severity of illness scoring systems in emergency department patients with infection Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation Bench-to-bedside review: avoiding pitfalls in critical care meta-analysis--funnel plots, risk estimates, types of heterogeneity, baseline risk and the ecologic fallacy Sepsis: in search of cure.Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.Recombinant human activated protein C inhibits integrin-mediated neutrophil migration Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation.Is the current management of severe sepsis and septic shock really evidence based?Hemodynamic goals in randomized clinical trials in patients with sepsis: a systematic review of the literature.Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis.Beyond heparin and warfarin: the new generation of anticoagulants.Effect of Drotrecogin alfa (activated) on platelet receptor expression in vitro.Practical aspects of treatment with drotrecogin alfa (activated)New parenteral anticoagulants in development.Alterations in the human lung proteome with lipopolysaccharide.Bundled care for septic shock: an analysis of clinical trials.Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study.Hydrogen gas presents a promising therapeutic strategy for sepsis.

P2860

Q21195024-3E79B242-07E3-4E4B-A956-5D47B97AC210 Q22305766-EF833802-18B2-421E-9C81-0E0C7E558119 Q24200439-80F47B87-0595-4182-9D87-AC2A7B40123A Q24201123-B909C78E-0A20-424C-90CB-442FF577E8CA Q24202128-3EFD3071-5DD9-4D2B-8015-A4BD04402B6C Q24235181-3F9AAAC9-A63D-4DBF-9828-C6DF638EB137 Q24242859-E31080B9-CC30-420D-AFA1-453AEABD723A Q24246064-7B72DE18-7408-49B1-A1AA-FA81FE3E00DE Q24282584-B58D1F5E-2CEB-4EE6-8242-CF79572E4781 Q24288920-5DB8268C-7C62-45D5-91B2-C68B300A35DB Q24537338-2353E5F9-6E1C-4ECE-B65A-B3CBA3FB241C Q24644984-3DD3FEE0-F0DA-4C3B-BA8B-28C063A0178F Q24816510-026EDA8F-6583-428A-864D-21990AE3B4DA Q25255548-A9D498A2-C119-4CA9-8DCB-226138D050E5 Q26865386-F75A4302-5A33-4197-8480-76A8CC953CF6 Q27013790-7587E2F7-AFB5-45D7-B343-F3DD9D130D14 Q27025096-BBD0972A-C627-45BD-B0F6-C93E7A0BE6A0 Q27027282-52603E67-C125-4B21-AE93-7FBEC1412BC6 Q27345533-255B7F25-1DDD-41AC-8CAE-3BB2F3D6CBAF Q27486641-0C1F6D37-53A8-4640-BF0D-982A0C30D0C2 Q28199912-BE8C66B1-23B2-49A2-B4E7-C7342583B363 Q28306781-A897CF68-EF19-411C-A169-B28F75015D8B Q28660920-C658C72C-9477-43A0-A905-889BFB71009E Q28756698-BA6B9A1A-1146-4986-9271-A64CB5B9A1BF Q30251753-A56B0CF0-1C1F-4FA1-9DD7-B873CC546076 Q30431534-E2B7A96B-0A09-4D53-87F5-E08B21CE7C09 Q30487220-B59437EC-F885-42E9-BA3B-304CD5FA84F6 Q30489456-E8A93D07-A3CA-4543-B1DE-9CFDAB7F7D2C Q33255319-FC58F64E-6FBF-4656-BB57-134D8677DBD7 Q33288475-560FE60D-7801-4C51-AE63-98DA337740DF Q33288889-6FE9508E-CC56-4D94-9612-13D844E823A6 Q33338424-C9D59363-C486-45EA-818B-39EEB3015D47 Q33374258-9DC53220-D079-4A8A-80CE-33AD5E985A4C Q33375997-57EBDDDF-1E2A-49D2-83CE-4345B5F39679 Q33378616-8F30145A-76B7-47D6-A330-5D960012953D Q33392647-80CC064A-4903-4466-9D63-403CF8104795 Q33443562-B9F79F55-0E85-496B-AB04-1890F1EBA749 Q33520432-B8164973-6E71-46A7-AF5E-97CC886F8BD7 Q33557838-58DE851C-1A1A-47D0-9104-1B07E7D40BA3 Q33562760-66F8B301-6C81-4CB1-9BA7-56979222DCAB

P2860

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

http://www.wikidata.org/entity/Q34455153

description

2005 nî lūn-bûn

@nan

2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

@ast

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

@en

type

label

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

@ast

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

@en

prefLabel

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

@ast

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

@en

P1433

Q34455153-3B5BB0CD-521B-4A82-A344-D82B5A253CC6

P1476

Q34455153-015194D7-C5BB-4910-B274-992B2CDFACEF

P2093

Q34455153-0742D317-8261-41FD-B126-8910E8C9FE90

Q34455153-125C7E2A-25DE-4DB5-89A3-463E370CB255

Q34455153-2726EF18-5747-41F0-A0E0-200421D31241

Q34455153-27CEA1F7-F2A0-472D-BF31-F1BC25D1496C

Q34455153-698DF020-F75D-4962-B426-0DE122045925

Q34455153-6FFEFDEC-66EE-4DAA-9C42-B781D63C8F50

Q34455153-71341527-BE26-448E-A7C9-4294902DF74D

Q34455153-7630ABB1-94B2-4243-8C82-22A8BBB7C59A

Q34455153-8409793A-55AF-4233-BB8E-78B8BB0A1A32

Q34455153-894B7D93-E5AE-444C-8D88-F0B86B3F23C7

P304

Q34455153-ACF02EF2-C922-4F67-BDE0-7A50EE33CBA9

P31

Q34455153-0A355D68-E822-4DE3-B2B1-C0C970197AFF

P356

Q34455153-619B496D-EEFF-423F-BF02-6424804D3E99

P407

Q34455153-5A4E93CE-3334-4B41-B7E5-F5167BA16608

P433

Q34455153-19C3622F-3EE4-42F9-B5F1-AFF958D752C3

P478

Q34455153-BB262252-B90A-4EDD-8C0E-9068D7EB48D7

P577

Q34455153-9CE0CE21-C217-41F6-9184-8CC7336DA996

P698

Q34455153-8911F11D-DE64-49B4-B80B-665DBB0A25DC

P921

Q34455153-80F8C100-D820-47D9-8285-A5998D8D6C76

P356

P1433

The New England Journal of Medicine

P1476

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

@en

P2093

Administration of Drotrecogin ...... e Sepsis (ADDRESS) Study Group

http://www.w3.org/2001/XMLSchema#string

Alvaro Rea-Neto

http://www.w3.org/2001/XMLSchema#string

Armin Sablotzki

http://www.w3.org/2001/XMLSchema#string

Barbara G Utterback

http://www.w3.org/2001/XMLSchema#string

Benjamin L Trzaskoma

http://www.w3.org/2001/XMLSchema#string

Bruno François

http://www.w3.org/2001/XMLSchema#string

Deepak Talwar

http://www.w3.org/2001/XMLSchema#string

Dominique Perrotin

http://www.w3.org/2001/XMLSchema#string

Edward Abraham

http://www.w3.org/2001/XMLSchema#string

Howard Levy

http://www.w3.org/2001/XMLSchema#string

P304

1332-1341

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA050935

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

353

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16192478

http://www.w3.org/2001/XMLSchema#string

P921